At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09969 INNOCARE
Market Closed 08-28 16:08:33
14.670
-0.160
-1.08%
High15.220Low14.600Vol4.81M
Open15.000D1 Closing14.830Amplitude4.18%
Mkt Cap25.92BTradable Cap21.92BTotal Shares1.77B
T/O71.26MT/O Rate0.32%Tradable Shares1.49B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Goldman Sachs Lifts Innocare Price Target to HK$22.71 on Robust Orelabrutinib Sales
Stock News  ·  08-28 16:40
Goldman Sachs Lifts Innocare Price Target to HK$22.71 on Robust Orelabrutinib Sales
InnoCare Pharma (SEHK:9969) Could Be 24% Undervalued Following Profit Turn
Simply Wall St.  ·  08-28 13:16
InnoCare Pharma (SEHK:9969) Could Be 24% Undervalued Following Profit Turn
InnoCare Pharma Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Simply Wall St.  ·  08-27
InnoCare Pharma Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Market Sentiment Stabilizes as Sanctions Prove Largely Symbolic; Tech Benchmarks Surge on Potential Dovish Fed Signals
Stock News  ·  08-25
Market Sentiment Stabilizes as Sanctions Prove Largely Symbolic; Tech Benchmarks Surge on Potential Dovish Fed Signals
InnoCare Pharma (SEHK:9969) Stock Jumps As Profit Arrives And Pipeline Risk Persists
Simply Wall St.  ·  08-25
InnoCare Pharma (SEHK:9969) Stock Jumps As Profit Arrives And Pipeline Risk Persists
Movement Alert｜INNOCARE Rises 5.08% in Regular Trading, H1 Earnings Show Return to Profitability with Revenue Up 55.5%
Market Focus  ·  08-25
Movement Alert｜INNOCARE Rises 5.08% in Regular Trading, H1 Earnings Show Return to Profitability with Revenue Up 55.5%
Press Release: InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved
Dow Jones  ·  08-24
Press Release: InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved
InnoCare Pharma Returns to Profit in H1
MT Newswires Live  ·  08-24
InnoCare Pharma Returns to Profit in H1
InnoCare Pharma Swings to RMB 239.67 Million Profit on 55.5% Revenue Jump in H1 2026
Bulletin Express  ·  08-24
InnoCare Pharma Swings to RMB 239.67 Million Profit on 55.5% Revenue Jump in H1 2026
China's InnoCare Pharma H1 Revenue Surges, Partly on Orelabrutinib Growth
Reuters  ·  08-24
China's InnoCare Pharma H1 Revenue Surges, Partly on Orelabrutinib Growth
INNOCARE Posts Interim Results with Profit Turnaround on Adjusted Basis
Stock News  ·  08-24
INNOCARE Posts Interim Results with Profit Turnaround on Adjusted Basis
InnoCare Schedules 24 Aug 2026 Board Meeting to Review 1H 2026 Interim Results
Bulletin Express  ·  08-11
InnoCare Schedules 24 Aug 2026 Board Meeting to Review 1H 2026 Interim Results
Why InnoCare Pharma (SEHK:9969) Is Up 12.9% After Dual Breakthrough Therapy Wins in Cancer and Autoimmune Disease - And What's Next
Simply Wall St.  ·  08-10
Why InnoCare Pharma (SEHK:9969) Is Up 12.9% After Dual Breakthrough Therapy Wins in Cancer and Autoimmune Disease - And What's Next
Movement Alert｜INNOCARE Rises 5.17% in Regular Trading, Multiple Autoimmune Pipeline Clinical Milestones Driving Sustained Uptrend
Market Focus  ·  08-10
Movement Alert｜INNOCARE Rises 5.17% in Regular Trading, Multiple Autoimmune Pipeline Clinical Milestones Driving Sustained Uptrend
InnoCare Pharma (SEHK:9969) Following Breakthrough Therapy News And The Undervalued Narrative
Simply Wall St.  ·  08-07
InnoCare Pharma (SEHK:9969) Following Breakthrough Therapy News And The Undervalued Narrative
InnoCare Issues 2.04 Million A-Shares Under Incentive Plan, Lifting Total Outstanding to 1.77 Billion
Bulletin Express  ·  08-05
InnoCare Issues 2.04 Million A-Shares Under Incentive Plan, Lifting Total Outstanding to 1.77 Billion
Breakthrough Psoriasis Data For Oral TYK2 Drug Might Change The Case For Investing In InnoCare Pharma (SEHK:9969)
Simply Wall St.  ·  07-29
Breakthrough Psoriasis Data For Oral TYK2 Drug Might Change The Case For Investing In InnoCare Pharma (SEHK:9969)
InnoCare Pharma's Phase III Trial of Fadeucravacitinib Meets Primary Endpoint
MT Newswires Live  ·  07-28
InnoCare Pharma's Phase III Trial of Fadeucravacitinib Meets Primary Endpoint
Hong Kong Stock Market Preview: Disease Prevention 15th Five-Year Plan Issued, SK Hynix Breaches IPO Price on Wall Street
Stock News  ·  07-28
Hong Kong Stock Market Preview: Disease Prevention 15th Five-Year Plan Issued, SK Hynix Breaches IPO Price on Wall Street
Movement Alert｜InnoCare Pharma Falls 5.04% in Regular Trading, Biotech Sector Sell-Off Compounds Post-Catalyst Profit-Taking
Market Focus  ·  07-17
Movement Alert｜InnoCare Pharma Falls 5.04% in Regular Trading, Biotech Sector Sell-Off Compounds Post-Catalyst Profit-Taking

Introduction

Company Name.
INNOCARE
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal T cell function. The Company conducts its businesses in domestic and overseas markets.
Issue price:
--